Market closed
ATAI Life Sciences/$ATAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Ticker
$ATAI
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
83
Website
ATAI Metrics
BasicAdvanced
$238M
-
-$0.80
0.78
-
Price and volume
Market cap
$238M
Beta
0.78
52-week high
$2.85
52-week low
$1.03
Average daily volume
4M
Financial strength
Current ratio
5.807
Quick ratio
4.374
Long term debt to equity
14.451
Total debt to equity
16.271
Interest coverage (TTM)
-20.88%
Management effectiveness
Return on assets (TTM)
-25.70%
Return on equity (TTM)
-62.77%
Valuation
Price to revenue (TTM)
695.056
Price to book
1.64
Price to tangible book (TTM)
1.64
Price to free cash flow (TTM)
-2.87
Growth
Revenue change (TTM)
-0.90%
Earnings per share change (TTM)
84.55%
3-year revenue growth (CAGR)
-74.58%
3-year earnings per share growth (CAGR)
-15.52%
What the Analysts think about ATAI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.
ATAI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ATAI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ATAI News
AllArticlesVideos
atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trial
Proactive Investors·2 days ago
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
GlobeNewsWire·2 days ago
atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollment
Proactive Investors·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $238M as of March 13, 2025.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of March 13, 2025.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.